Probiotic Bifidobacteria Mitigate the Deleterious Effects of
            <i>para</i>
            -Cresol in a Drosophila melanogaster Toxicity Model

Stuivenberg, Gerrit A.; Chmiel, John A.; Akouris, Polycronis P.; Burton, Jeremy P.; Reid, Gregor

doi:10.1128/msphere.00446-22

Cited by 7 publications

(14 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors concluded that the findings correlated with a normalized intestinal microbiota [40,41]. Other explanations are feasible, such as the bifidobacteria directly sequestering p-cresol from the surrounding environment, as we have shown [27]. The data suggest that some strains of bifidobacteria are more effective than others at reducing gut microbiota-derived p-cresol, which points to the importance of proper strain selection in commercial probiotics.…”

Section: Introductionsupporting

confidence: 66%

“…Each tube was spiked with 0.2 mg/mL p-cresol. The concentration of p-cresol mimicked its physiological extremes found in the human intestinal tract [27,58]. The inoculums were incubated anaerobically for 24 h at 37 • C under stationary conditions.…”

Section: P-cresol Clearance In a Simulated Colonic Environmentmentioning

confidence: 99%

“…Samples from the simulated colonic environment were prepared for HPLC analysis using a previously described method [27]. Succinctly, each sample was centrifuged at 4500× g for 10 min at ambient temperature.…”

Section: Sample Preparation and Hplc Analysismentioning

confidence: 99%

“…p-Cresyl sulfate is an especially important toxin sourced from the bacterial metabolism of tyrosine and phenylalanine. Microbial fermentation of these amino acids in the gut yields the toxin precursor, p-cresol, which is absorbed from the intestinal environment to be sulfated in the liver, after which p-cresyl sulfate enters the circulation and binds albumin [27][28][29][30][31][32][33]. The accumulation of p-cresol and p-cresyl sulfate is known to induce oxidative stress and renal inflammation, decrease kidney cell viability, and enhance NADPH oxidase activity [34], each of which are manifestations commonly observed with the disease.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Supplementing Yogurt with Probiotic Bifidobacteria to Counter Chronic Kidney Disease

et al. 2023

Self Cite

View full text Add to dashboard Cite

Chronic kidney disease (CKD) disproportionately affects populations in developing countries. In sub-Saharan Africa, CKD prevalence is high (12–23%) and is associated with cardiovascular manifestations. Uremic toxins, especially p-cresol and p-cresyl sulfate, are associated with the disease. Reducing uremic toxins in the body slows disease progression and improves patient outcomes. Probiotic Bifidobacterium breve HRVD521-US, B. animalis HRVD524-US, B. longum SD-BB536-JP, and B. longum SD-CECT7347-SP internalize p-cresol and improve longevity in vivo. In 2002, Tanzanian communities were taught to produce probiotic yogurt (Fiti®) supplemented with Lacticaseibacillus rhamnosus GR-1. This has expanded to over 100 community producers across the country. To produce yogurt that could reduce the burden of CKD by sequestering uremic toxins, we decided to test the addition of p-cresol-clearing bifidobacterial strains. By repeating the Fiti® production process performed in Tanzanian communities and adding a bifidobacterial strain, we found that they were successfully incorporated into the yogurt without any detrimental effect on sensory properties or viable counts. Three of the four strains significantly reduced p-cresol when added to a simulated colonic environment. In conclusion, this study has shown that Fiti® sachets provided to Tanzanian communities to produce yogurt can be supplemented with strains that can potentially confer additional health benefits.

show abstract

Section: Introductionsupporting

confidence: 66%

Section: P-cresol Clearance In a Simulated Colonic Environmentmentioning

confidence: 99%

Section: Sample Preparation and Hplc Analysismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Supplementing Yogurt with Probiotic Bifidobacteria to Counter Chronic Kidney Disease

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…The ability to up-regulate epithelial junction proteins or antimicrobial compounds could be added as a test for potential application [28] . A new concept suggests that some lactobacilli have the ability to dampen ATP production and impede Ca 2+ influx and contraction, which could be an assessment tool [29] , as could the ability of certain Bifidobacterium strains to internalize the renal toxin p-cresol [30] . The latter experiments were done in a Drosophila model, which is a useful tool for assessing parameters of urolithiasis [31] .…”

Section: How To Select Probiotic Strains To Reduce the Risk Of Uti An...mentioning

confidence: 99%

Perspective: microbial interventions in the urinary tract

Reid¹

2023

Microbiome Res Rep

View full text Add to dashboard Cite

Despite multiple advances in medicine, the management of urinary tract infections (UTIs) in women has remained stalled for decades. To prevent the development of symptomatic recurrences, low-dose antibiotics are the mainstay, while alternative approaches have been attempted with limited success. The use of probiotics was first considered forty years ago, and while some promising studies have been published, additional evidence in larger patient groups is needed to recommend specific strains as a primary preventive regimen. Overall, the role of beneficial microbes in reducing the risk of UTI and other urological diseases, such as urolithiasis, remains a target for researchers. The aim of this perspective is to offer a viewpoint on the status of this approach and recommendations for how to develop novel probiotic therapies.

show abstract

Geroprotective potential of microbiome modulators in the Caenorhabditis elegans model

Miller,

Mathai,

Yadav

et al. 2023

GeroScience

View full text Add to dashboard Cite

Aging is associated with cellular and physiological changes, which significantly reduce the quality of life and increase the risk for disease. Geroprotectors improve lifespan and slow the progression of detrimental aging-related changes such as immune system senescence, mitochondrial dysfunction, and dysregulated nutrient sensing and metabolism. Emerging evidence suggests that gut microbiota dysbiosis is a hallmark of aging-related diseases and microbiome modulators, such as probiotics (live bacteria) or postbiotics (non-viable bacteria/bacterial byproducts) may be promising geroprotectors. However, because they are strain-specific, the geroprotective effects of probiotics and postbiotics remain poorly understood and understudied. Drosophila melanogaster, Caenorhabditis elegans, and rodents are well-validated preclinical models for studying lifespan and the role of probiotics and/or postbiotics, but each have their limitations, including cost and their translation to human aging biology. C. elegans is an excellent model for large-scale screening to determine the geroprotective potential of drugs or probiotics/postbiotics due to its short lifecycle, easy maintenance, low cost, and homology to humans. The purpose of this article is to review the geroprotective effects of microbiome modulators and their future scope, using C. elegans as a model. The proposed geroprotective mechanisms of these probiotics and postbiotics include delaying immune system senescence, preventing or reducing mitochondrial dysfunction, and regulating food intake (dietary restriction) and metabolism. More studies are warranted to understand the geroprotective potential of probiotics and postbiotics, as well as other microbiome modulators, like prebiotics and fermented foods, and use them to develop effective therapeutics to extend lifespan and reduce the risk of debilitating aging-related diseases.

show abstract

Probiotic Bifidobacteria Mitigate the Deleterious Effects of para -Cresol in a Drosophila melanogaster Toxicity Model

Cited by 7 publications

References 75 publications

Supplementing Yogurt with Probiotic Bifidobacteria to Counter Chronic Kidney Disease

Supplementing Yogurt with Probiotic Bifidobacteria to Counter Chronic Kidney Disease

Perspective: microbial interventions in the urinary tract

Geroprotective potential of microbiome modulators in the Caenorhabditis elegans model

Contact Info

Product

Resources

About